血塞通注射液治疗急性脑梗死恢复期(瘀血阻滞型)的临床研究

目的探讨血塞通注射液治疗急性脑梗死恢复期患者(瘀血阻滞型)的临床疗效。方法选取2018年2月—2020年3月南阳市中心医院收治的98例脑梗死恢复期(瘀血阻滞型)患者,随机分为对照组和治疗组,每组各49例。对照组给予西医常规治疗,治疗组在对照组基础上静脉滴注血塞通注射液,0.4 g/次,1次/d。两组均连续治疗2周。观察两组的临床疗效,比较两组神经功能(NIHSS)评分、SS-QOL量表评分、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、基质金属蛋白酶-2(MMP-2)、基质细胞衍生因子-1(SDF-1)、血管内皮生长因子(VEGF)、S100蛋白(S100B)、血红素加氧酶(HO-1)、内皮祖细胞(EPCs)的变化情况。结果治疗后,治疗组总有效率93.88%,显著高于对照组的73.47%(P0.05)。治疗后,两组NIHSS评分显著降低,但SS-QOL评分则升高(P0.05);治疗后,治疗组NIHSS评分低于对照组,但SS-QOL评分高于对照组(P0.05)。治疗后,两组Hs-CRP、Hcy、MMP-2均显著降低(P0.05);治疗后,治疗组Hs-CRP、Hcy、MMP-2低于对照组(P0.05)。治疗后两组VEGF、SDF-1水平均显著降低(P0.05);治疗后,治疗组VEGF、SDF-1水平低于对照组(P0.05)。治疗后两组血清S100B均降低,但HO-1、EPCs较前升高(P0.05);治疗后,治疗组S100B低于对照组,但HO-1、EPCs高于对照组(P0.05)。结论血塞通注射液治疗瘀血阻滞型急性脑梗死恢复期患者具有较好的临床疗效,促进神经功能修复,减轻缺血再灌注伤,有助于促进侧枝循环形成,提高抗氧化能力,具有一定的临床推广应用价值。

Clinical study of Xuesaitong Injection in treatment of acute cerebral infarction in recovery stage (blood stasis block type)

Objective To investigate the clinical effect of Xuesaitong Injection in treatment of acute cerebral infarction in recovery stage (blood stasis block type). Methods A total of 98 patients with cerebral infarction in recovery stage (blood stasis type) admitted to Nanyang Central Hospital from February 2018 to March 2020 were selected and randomly divided into control group and treatment group, 49 patients in each group. The control group was given conventional western medicine treatment. Patients in the treatment group were iv administered with Xuesaitong Injection on the basis of the control group, 0.4 g/time, once daily. Both groups were treated continuously for 2 weeks. After treatment, the clinical efficacy was evaluated, and the changes of NIHSS score, SS-QOL score, hs-CRP, Hcy, MMP-2, VEGF, SDF-1, S100B, HO-1, and EPCs in two groups were compared. Results After treatment, the total effective rate of the treatment group was 93.88%, significantly higher than that of the control group (73.47%, P<0.05). After treatment, NIHSS score was significantly decreased in both groups, but SS-QOL score was increased (P<0.05). After treatment, the NIHSS score of the treatment group was lower than that of the control group, but the SS-QOL score was higher than that of the control group (P<0.05). After treatment, hs-CRP, Hcy and MMP-2 in two groups were significantly decreased (P<0.05). After treatment, hs-CRP, Hcy and MMP-2 in the treatment group were lower than those in the control group (P<0.05). After treatment, the levels of VEGF and SDF-1 in two groups were significantly decreased (P<0.05). After treatment, the levels of VEGF and SDF-1 in treatment group were lower than those in control group (P<0.05). After treatment, serum S100B was decreased in both groups, but HO-1 and EPCs were increased (P<0.05). After treatment, S100B in the treatment group was lower than that in the control group, but HO-1 and EPCs in the treatment group were higher than that in the control group (P<0.05). Conclusion Xuesaitong Injection has good clinical efficacy in treatment of acute cerebral infarction in recovery stage (blood stasis block type), and can promotes nerve function repair, reduces ischemia reperfusion injury, and also can help to promote the formation of collateral circulation, improves antioxidant capacity, which has certain clinical application value.